HSandM Magazine

Menu
  • Home
  • About
  • Headlines
  • Top Articles
    • Executive Spotlights
    • Round Tables
    • Industry Trends
    • Talent Trends
    • Great Minds
    • Innovation Showcase
    • Top Industry Lists
    • Why I Work in Healthcare
  • Submit an Innovation!
  • Advertise
  • Agency Directory
  • FREE SUBSCRIPTION!
Menu

HSandM Magazine

Search

Nov/Dec2015

Latest stories

Building Tomorrow’s Commercial Organization

Senior Director Tells You How To Get Into The Hospital (As a rep, of course)

BY THE NUMBERS

More stories

  • in Innovation Showcase

    Customized Customer Engagement

    by hsandm November 1, 2015, 12:00 pm

  • in Motivideos

    MOTIVIDEOS

    by hsandm November 1, 2015, 12:00 pm

  • in Top Industry Lists

    HS&M™ TOP 100 HEALTHCARE COMPANIES

  • in Industry Trends

    Forecasting Pharma’s Future

    by hsandm November 1, 2015, 12:00 pm

  • in Round Table

    Big Data and the New World

    by hsandm November 1, 2015, 12:00 pm

  • in Industry Trends

    VPOC: Virtual Point Of Care

    by hsandm November 1, 2015, 12:00 pm

Trending Now

  • Headlines

    649 Views0 Comments

    in Headlines

    Alladapt Announces Completion of Oversubscribed $119 Million Institutional Financing

    Menlo Park, CA., June 22, 2022 (GLOBE NEWSWIRE) — Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company developing prescription therapeutics to address IgE-mediated food allergy, announced today the closing of a $119 million financing round led by Enavate Sciences, a portfolio company created by Patient Square Capital. Additional investors participating in the financing include Alladapt’s founding investor, Gurnet Point Capital, along with new investors Allerfund, Novartis (NYSE: NVS), Red Tree Venture Capital, and WestRiver Group. More

    by hsandm June 22, 2022, 4:56 pm

    Read More

  • Headlines

    393 Views0 Comments

    in Headlines

    Angiex Strengthens its Leadership Team with the Appointment of Marty J. Duvall as Chief Executive Officer

    Cambridge, MA, June 22, 2022 (PRNewswire) — Angiex, developer of Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapies for solid cancers, has appointed Marty J. Duvall as chief executive officer and member of its board of directors. More

    by hsandm June 22, 2022, 4:24 pm

    Read More

  • Headlines

    745 Views0 Comments

    in Headlines

    Inimmune’s new CEO Alan Joslyn takes the helm

    Missoula, MT., June 21, 2022 (PRNewswire) — Inimmune Corp., a leader in developing the next generation of vaccines and immunotherapeutics, announced today that Dr. Alan Joslyn has been appointed President and Chief Executive Officer of the company. Dr. Joslyn will also join the Inimmune Board of Directors as CEO. More

    by hsandm June 21, 2022, 4:50 pm

    Read More

  • Headlines

    2 Shares492 Views0 Comments

    in Headlines

    Precision BioSciences and Novartis ink 1.5B In Vivo Gene Editing Collaboration

    Durham, N.C. June 21, 2022 (BUSINESS WIRE) — Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma AG (the “Agreement”). As part of the Agreement, Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a “safe harbor” location in the genome as a potential one-time transformative treatment option for diseases including certain hemoglobinopathies such as sickle cell disease and beta thalassemia. More

    by hsandm June 21, 2022, 4:17 pm

    Read More

  • Headlines

    8 Shares869 Views0 Comments

    in Headlines

    Israel’s Aidoc raises $110m for AI tech that reads imaging scans

    New York, NY, June 20, 2022 (The Times of Israel) — Aidoc, a maker of AI-based software that helps radiologists read medical scans and alerts them to strokes or pulmonary embolisms, has pulled in a $110 million Series D investment round to expand the development of its technology, sales and its market reach, the company said last week. More

    by hsandm June 20, 2022, 4:47 pm

    Read More

  • Headlines

    11 Shares993 ViewsComments Off on Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

    in Headlines

    Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

    Philadelphia, PA.,  June 8, 2022 (PRNewswire) — Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to developing a best-in-class, novel therapy for the treatment of hypertension, today announced the completion of an oversubscribed and up-sized $118 million Series B financing. More

    by hsandm June 8, 2022, 7:47 pm

    Read More

Categories

  • Agency Directory
  • Digital Magazine
  • Editorial Board
  • Executive Spotlight
  • Great Minds
  • Headlines
  • Industry Trends
  • Innovation Showcase
  • Leadership
  • Motivideos
  • Round Table
  • Talent Trends
  • Top Industry Lists
  • Uncategorized
  • Why I Work in Healthcare

© 2022 by CL Media, Inc.

  • Home
  • Contact us
  • Privacy Policy
  • Terms of Use
  • Sign Up!
Back to Top
Close
  • Home
  • About
  • Headlines
  • Top Articles
    • Executive Spotlights
    • Round Tables
    • Industry Trends
    • Talent Trends
    • Great Minds
    • Innovation Showcase
    • Top Industry Lists
    • Why I Work in Healthcare
  • Submit an Innovation!
  • Advertise
  • Agency Directory
  • FREE SUBSCRIPTION!
  • facebook
  • twitter
  • instagram
  • pinterest
  • youtube

Log In

Sign In

Forgot password?

Forgot password?

Enter your account data and we will send you a link to reset your password.

Back to Login

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

To use social login you have to agree with the storage and handling of your data by this website. %privacy_policy%

Accept

Add to Collection

  • Public collection title

  • Private collection title

No Collections

Here you'll find all collections you've created before.